Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

Immune checkpoint blockade therapy targeting programmed cell death protein 1 (PD-1) has
revolutionized the landscape of multiple human cancer types, including head and neck …

Importance Programmed cell death ligand 1 inhibitors combined with chemotherapy has
changed the approach to first-line treatment in patients with extensive-stage small cell lung …

Background Extensive-stage small-cell lung cancer (ES-SCLC) is associated with poor
prognosis and treatment options are scarce. Immunotherapy has shown robust clinical …

Background Recently, therapeutic antibodies against programmed cell death 1 (PD-1) and
its ligand (PD-L1) have exerted potent anticancer effect in a variety of tumors. However …

Background Camrelizumab, an anti-PD-1 antibody, has shown moderate efficacy in
oesophageal squamous cell carcinoma. Apatinib, a selective inhibitor of VEGFR2, has a …

Purpose: This study aimed to assess the antitumor activity and safety of neoadjuvant
chemotherapy combined with PD-1 inhibitor camrelizumab in patients with locally advanced …

Background Treatment options for patients with high-risk chemorefractory or relapsed
gestational trophoblastic neoplasia are scarce. The synergistic antitumour effect of …

Inhibition of angiogenesis has been demonstrated to be an efficacious strategy in treating
several tumors. Vascular endothelial growth factor (VEGF) is the most important protein with …

Treatments for NSCLC patients with EGFR‐TKI resistance are limited. Given that
immunotherapy and antiangiogenic agents may have synergistic antitumor effects, we …